Beyond neurological disease: New targets for edaravone (Review)

Kikuchi, Kiyoshi; Uchikado, Hisaaki; Miyagi, Naohisa; Morimoto, Yoko; Ito, Takashi; Tancharoen, Salunya; Miura, Naoki; Miyata, Kei; Sakamoto, Rokudai; Kikuchi, Chiemi; Iida, Narumi; Shiomi, Naoto; Kuramoto, Terukazu; Kikuchi, Kôichi

doi:10.3892/ijmm.2011.795

Cited by 21 publications

(11 citation statements)

References 85 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent free-radical and protein carbonyl scavenger and inhibitor of lipid peroxidation [57-58]. Protein carbonylation and carbonyl stress via aldehydes occur in COPD and hence edaravone has the potential to protect the lungs against the effects of these oxidative products [59-60].…”

Section: Lipid Peroxidation and Protein Carbonylation Inhibitors/blocmentioning

confidence: 99%

Antioxidant pharmacological therapies for COPD

Rahman

MacNee

2012

Current Opinion in Pharmacology

109

View full text Add to dashboard Cite

Increased oxidative stress occurs in the lungs and systemically in COPD, which plays a role in many of the pathogenic mechanisms in COPD. Hence, targeting local lung and systemic oxidative stress with agents that modulate the antioxidants/redox system or boost endogenous antioxidants would be a useful therapeutic approach in COPD. Thiol antioxidants (N-acetyl-L-cysteine and N-acystelyn, carbocysteine, erdosteine, and fudosteine have been used to increase lung thiol content. Modulation of cigarette smoke induced oxidative stress and its consequent cellular changes have also been reported to be effected by synthetic molecules, such as spin traps (α-phenyl-N-tert-butyl nitrone), catalytic antioxidants (superoxide dismutase [ECSOD] mimetics), porphyrins, and lipid peroxidation and protein carbonylation blockers/inhibitors (edaravone and lazaroids/tirilazad). Pre-clinical and clinical trials have shown that these antioxidants can reduce oxidative stress, affect redox and glutathione biosynthesis genes, and pro-inflammatory gene expression. In this review the approaches to enhance lung antioxidants in COPD and the potential beneficial effects of antioxidant therapy on the course of the disease are discussed.

show abstract

Section: Lipid Peroxidation and Protein Carbonylation Inhibitors/blocmentioning

confidence: 99%

Antioxidant pharmacological therapies for COPD

Rahman

MacNee

2012

Current Opinion in Pharmacology

109

View full text Add to dashboard Cite

show abstract

“…Edaravone has been widely used in patients with AIS since April 2001 in Japan, because many clinical and experimental studies have demonstrated neurovascular protective effects [11–15]. Furthermore, edaravone has anti-apoptotic, anti-necrotic, and anti-inflammatory cytokine effects, as well as scavenging free radicals in cardiovascular diseases and stroke, showing protective effects in the heart, vessel, and brain in experimental studies [16–19]. Moreover, edaravone has preventive effects on myocardial injury following ischemia and reperfusion (I/R) in patients with acute myocardial infarction (AMI) [20].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease

Kikuchi

Tancharoen

Takeshige

et al. 2013

IJMS

View full text Add to dashboard Cite

Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001. Free radicals play an important role in the pathogenesis of a variety of diseases, such as cardiovascular diseases and stroke. Therefore, free radicals may be targets for therapeutic intervention in these diseases. Edaravone shows protective effects on ischemic insults and inflammation in the heart, vessel, and brain in experimental studies. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic, and anti-cytokine effects in cardiovascular diseases and stroke. Edaravone has preventive effects on myocardial injury following ischemia and reperfusion in patients with acute myocardial infarction. Edaravone may represent a new therapeutic intervention for endothelial dysfunction in the setting of atherosclerosis, heart failure, diabetes, or hypertension, because these diseases result from oxidative stress and/or cytokine-induced apoptosis. This review evaluates the potential of edaravone for treatment of cardiovascular disease, and covers clinical and experimental studies conducted between 1984 and 2013. We propose that edaravone, which scavenges free radicals, may offer a novel option for treatment of cardiovascular diseases. However, additional clinical studies are necessary to verify the efficacy of edaravone.

show abstract

“…However, only 1-2% of patients can receive thrombolytic therapy mainly due to the short time window (no more than 3–6 h after stroke) and the possible complication such as hemorrhagic transformation (HT) and brain edema [2]. Although edaravone, a free radical scavenger [3, 4], has been used in Asian countries for many years, it is still not approved by the United States and Europe because of its side effects in liver and kidney and only a small clinical trial found that edaravone might improve outcomes [5–7]. Thus, additional effective new drugs are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Catalpol Induces Neuroprotection and Prevents Memory Dysfunction through the Cholinergic System and BDNF

Wan

Xue²,

Zhu

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

To investigate the role and mechanism of catalpol on neuroprotective effects and memory enhancing effects simultaneously, neuroprotective effects of catalpol were assessed by neurological deficits score, TTC staining, and cerebral blood flow detecting. Morris water maze was employed to investigate its effects on learning and memory and then clarify its possible mechanisms relating the central cholinergic system and BDNF. Edaravone and oxiracetam were used for positive control drugs based on its different action. Results showed that catalpol and edaravone significantly facilitated neurological function recovery, reduced infarction volume, and increased cerebral blood flow in stroke mice. Catalpol and oxiracetam decreased the escape latency significantly and increased the numbers of crossing platform obviously. The levels of ACh, ChAT, and BDNF in catalpol group were increased in a dose-dependent manner, and AChE declined with a U-shaped dose-response curve. Moreover, the levels of muscarinic AChR subtypes M1 and M2 in hippocampus were considerably raised by catalpol. These results demonstrated that catalpol may be useful for neuroprotection and memory enhancement, and the mechanism may be related to the central cholinergic system.

show abstract

Beyond neurological disease: New targets for edaravone (Review)

Abstract: Abstract. Free radicals play major roles in the pathogenesis of tissue damage in many diseases and clinical conditions, and the removal of free radicals may offer a treatment option.

Cited by 21 publications

References 85 publications

Antioxidant pharmacological therapies for COPD

Antioxidant pharmacological therapies for COPD

The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease

Catalpol Induces Neuroprotection and Prevents Memory Dysfunction through the Cholinergic System and BDNF

Contact Info

Product

Resources

About